Galena
Biopharma, a developer of targeted oncology treatments that address major unmet
needs in cancer care, reported today it will be presenting at the Oppenheimer
24th Annual Healthcare Conference in New York City. The company’s President and
CEO, Mark J. Anh, PhD, will be presenting a corporate update at the conference,
taking place next week on Tuesday, December 10, 2013 at 10:55 am EST at the
Crowne Plaza Hotel.
The
presentation will be webcast, available in the Investors section at:
www.galenabiopharma.com.
Galena
Biopharma currently has a strong clinical pipeline in place. The primary
therapeutic solution the company has in development is NeuVax, a cancer
immunotherapy that takes advantage of the immune system’s power to locate and
destroy HER2-presenting cells. The HER2 is a well-established target for
clinical action against breast carcinoma. It is injected into the body to
destroy these cells that are currently present as well as act as an inhibitor
against future appearances of these cells. The immunotherapy is currently in
Phase III testing for FDA approval against breast cancer recurrence.
The
company is also developing Folate Binding Protein-E39, a targeted vaccine aimed
at preventing the recurrence of ovarian, endometrial, and breast cancers. It is
currently in Phase I testing of FDA approval.
The
company released in October Abstral®. That is a sublingual (under the tongue)
fentanyl tablet indicated for the management of breakthrough pain in patients
with cancer, 18 years of age and older, who are already receiving, and who are
tolerant to, opioid therapy for their persistent baseline cancer pain.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
